OncoSec Medical Featured on San Francisco’s KGO-TV Channel 7

News Segment Focuses on Use of ImmunoPulse to Treat Metastatic Melanoma

Business Wire

SAN DIEGO--(BUSINESS WIRE)--

OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, was featured in a news segment airing July 17 on San Francisco’s ABC affiliate KGO-TV Channel 7.

The news segment details the potential of OncoSec’s ImmunoPulse DNA-based immunotherapy to treat metastatic melanoma, and profiles one California patient who has undergone the therapy.

During the segment, Dr. Adil Daud, principal investigator of OncoSec’s Phase II metastatic melanoma trial, remarks about ImmunoPulse: “You can have responses not just to the tumors you've injected...but even to tumors you haven’t touched, even to tumors in other parts of the body that you have [not] done anything to or injected. [W]e think that it’s an immune memory that forms.”

To view the KGO-TV news segment and read the accompanying article (“Doctors use electricity to boost cancer treatment”), please visit the following link: http://abclocal.go.com/kgo/story?section=news/health&id=9174596

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:
Investor Relations:
OncoSec Medical Inc.
Amy Chan, 855-662-6732
investors@oncosec.com
or
Public Relations:
Dian Griesel Inc.
Laura Radocaj, 212-825-3210
lradocaj@dgicomm.com

Rates

View Comments